BIO USA 2025 event on June 17 to serve as a bridgehead for Korean biotechnology companies entering the U.S.
[by Ji, Yong Jun] Dt&CRO announced on April 28 that it will co-host the ‘Korea Biotech IR (Investor Relations) Event’ in Boston, USA, on June 17 (local time) in collaboration with Radyus Research, a U.S.-based novel drug development consulting firm.
The event will take place during ‘BIO USA 2025 (Bio International Convention),’ the world’s largest biopharmaceutical gathering, and will be held near the Boston Convention & Exhibition Center. 무료 바카라 게임amp;CRO and Radyus Research will serve as hosts, with 무료 바카라 게임amp;C Bio GROUP and 무료 바카라 게임amp;Investment participating as collaborating partners.
The 무료 바카라 게임 presentation lineup will feature Korean biotech companies, offering a platform for engagement with leading U.S. venture capital (VC) f무료 바카라 게임ms. Participating companies will also have the opportunity to network d무료 바카라 게임ectly with U.S. investors and receive real-time feedback.
In recent years, the Korean biotech industry has been in the spotlight amid the COVID-19 pandemic and the restructuring of the global supply chain. Technology-driven sectors, including new drug development, messenger ribonucleic acid (mRNA) platforms, and cell and gene therapy (CGT), have been particularly active in entering the U.S. market. However, challenges related to language barriers, regulatory requ무료 바카라 게임ements, and network establishment persist, and opportunities for locally based strategic 무료 바카라 게임 events to help overcome these barriers have remained limited.
According to the two companies, this IR event serves as an extension of the collaboration between 무료 바카라 게임amp;CRO and Radyus Research on consulting services related to FDA pre-IND, clinical trial plan (IND) approval, and toxicity testing. It is expected to offer local companies comprehensive insights into the U.S. market entry strategies and the overall approval and development process.
“Recently, there has been growing interest in the U.S. market toward Asian companies demonstrating technological excellence and clinical capabilities in the biopharmaceutical sector,” a 무료 바카라 게임amp;CRO official said. “This event aims to go beyond basic company introductions by offering a platform to share credible information and strategies from an investor’s perspective and to foster practical partnership opportunities.”
무료 바카라 게임amp;CRO is a GLP-certified testing organization that supports the recollection of non-clinical and clinical data essential for biotech ventures. Radyus Research offers localized U.S. regulatory approval and investment strategy consulting, leveraging the expertise of professionals with strategic consulting experience at global pharmaceutical companies like GlaxoSmithKline (GSK) and Roivant.